Scribe Therapeutics, Inc.

SCTX

Nasdaq; healthcare; SIC 2836, Biological Products, (No Diagnostic Substances); CIK 0001853921

None


No letter

0 of 14 inputs computable; 7 are required, with a score in every sleeve

Scoreboard


Warnings	thin data not computable: dilution, short runway, degenerate inputs, distress, fortress balance sheet
Inputs computable	0 of 14
Graded from	filings received through n/a None days before the rescan; latest periodic filing 10-Q received Sep 2, 2026
Last close	$15.76 2026-11-06; market equity $298.4M; no price enters the letter

Share price, twelve months to the rescan



Split-adjusted close. Each lollipop is a rescan and carries the letter held then.

Letter at every rescan, 2012 to 2026



Sector percentile at each rescan, stronger toward the top; facts filed by each date only.

The fourteen inputs

lower percentile is stronger; sleeves and inputs within a sleeve carry equal weight

Input	Value	Peer median	Percentile, 0 to 100	Pct	Peers	Period end
Profitability						
Gross profitability	not computable	32.3%				
one or more required annual facts are missing						
Return on invested capital	not computable	9.3%				
one or more required annual facts are missing						
Accruals ratio	not computable	(6.6%)				
one or more required annual facts are missing						
Gross margin stability, five years	not computable	2.8 pts				
five annual gross margins are required; found 0						
Solvency						
Twelve-month failure probability	not computable	0.08%				
four consecutive discrete net-income quarters are required; found 2						

Not investment advice. Informational and educational only. Data from SEC EDGAR, may contain errors, is not warranted. The grade ranks reported financial condition and is not a return forecast.

Altman Z double-prime	not computable	(0.37)
one or more required annual facts are missing		
Net debt to EBITDA	not computable	1.82x
one or more required annual facts are missing		
Interest coverage	not computable	(4.51x)
one or more required annual facts are missing		
Current ratio	not computable	2.94x
one or more required annual facts are missing		
Growth and financing		
Revenue growth, three-year compound	not computable	10.0%
four annual observations are required; found 0		
Free cash flow growth, three-year compound	not computable	10.9%
four consecutive annual FCF observations are required; found 0		
Reinvestment rate	not computable	37.1%
one or more required annual facts are missing		
Asset growth, three years	not computable	2.2%
four annual observations are required; found 0		
Net share issuance, one year	not computable	2.5%
two annual share counts are required; found 0		

Warnings

1 of 7 checks triggered; none of them enters the letter

Check	Measured
Thin data	0 of 14 grade factors are computable; minimum is 7

What the price implies

at the 2026-11-06 close; none of these enters the grade

Measure	Value	Peer median	Percentile
Twelve-month price change, skipping the latest month	not computable	(2.1%)	
Distance from 52-week high	(57.9%)	(30.5%)	22
EBIT to enterprise value	not computable	(1.5%)	
Free cash flow yield	not computable	(1.0%)	
Book value to price	(0.55)	0.29	3
Sales to price	not computable	0.30	
Composite equity issuance, five years	not computable	21.4%	
Relative strength against the sector, log excess return	not computable	(0.19)	

Diagnostics

shown on every report; none enters the grade

Measure	Value
Piotroski F-score None of 9, period end	
Return on assets above zero	fail
Operating cash flow above zero	fail
Return on assets improved	fail
Operating cash flow exceeds net income	fail
Long-term leverage fell	fail
Current ratio improved	fail
No new shares issued	fail
Gross margin improved	fail
Asset turnover improved	fail
Cash, filings, liquidity	
Cash and equivalents	n/a

Not investment advice. Informational and educational only. Data from SEC EDGAR, may contain errors, is not warranted. The grade ranks reported financial condition and is not a return forecast.

Operating cash flow, four quarters	n/a
Months of runway	not finite
Days since last periodic filing	66 (10-Q received Sep 2, 2026)
Median daily dollar volume, 63 sessions	$6.9M

Sources

every fact behind the inputs; each row links to its filing index on sec.gov

#	Concept	XBRL tag	Value	Period end	Received	Form	Accession